Health Information Search Results
Peer Reviewed Scientific Research Reports.
|<< Prev 20 ||Showing 1 to 7 of 7 Matches||Next 20 >>|
1. Migrainous vertigo: prevalence and impact on quality of life.
Match Strength: 5.773
OBJECTIVE: To investigate the epidemiology of migrainous vertigo (MV) in the general population by assessing prevalence, clinical features, comorbid conditions, quality of life, and health care utilization. METHODS: We screened a representative sample of the adult population in Germany (n = 4,869) for moderate or severe dizziness/vertigo and followed up with validated neurotologic telephone interviews (n = 1,003). Diagnostic criteria for MV were as follows: 1) recurrent vestibular vertigo; 2) migraine according to the International Headache Society; 3) migrainous symptoms during at least two ... Read More »
» Published in Neurology. 2006 Sep 26;67(6):1028-33.
2. Migraine-related vertigo: diagnostic criteria and prophylactic treatment.
Match Strength: 4.333
OBJECTIVE/HYPOTHESIS: The objective of this prospective, observational study was to evaluate the efficacy of migraine pharmacologic prophylaxis on a group of vertiginous patients considered affected by migraine-related vertigo on the basis of precise criteria of inclusion. METHODS: Fifty-three patients affected by migraine-related vertigo were selected from a cohort of 652 vertiginous patients referred to our Dizziness Unit from March 2001 to June 2005. Inclusion criteria were at least five vertigo attacks occurred in any period of time or dizziness and/or positional vertigo for at least 6 ... Read More »
» Published in Laryngoscope. 2006 Oct;116(10):1782-6.
3. Oxcarbazepine monotherapy in children and adolescents: a single-center clinical experience.
Match Strength: 3.105
This single-center analysis evaluated the efficacy of oxcarbazepine monotherapy in children and adolescents. A retrospective chart review identified 60 patients (male=33, female=27) aged 6 months to 17.8 years (mean age 8.2+/-4.7 years) with partial onset epilepsy receiving oxcarbazepine monotherapy. The range of oxcarbazepine dose was 6-71 mg/kg/day (mean 26.3+/-11.4 mg/kg/day). The duration of therapy ranged from 3 months to 8 years (mean duration 16.7+/-14.3 months). Fifty-one patients (85%) achieved>or=50% reduction in seizure frequency, and 25 of 60 patients (42%) achieved seizure ... Read More »
» Published in Pediatr Neurol. 2006 Oct;35(4):235-9.
4. Efficacy and safety of tamsulosin OCAS.
Match Strength: 2.992
The efficacy and safety of a new tablet formulation of tamsulosin (the oral-controlled absorption system: OCAS(R)) have been assessed in several clinical trials. In a phase IIb and a phase IIIa trial, the appropriate dose of the tamsulosin tablet for clinical practice was determined. All tested doses of tamsulosin OCAS (0.4, 0.8 and 1.2 mg) improved the lower urinary symptoms (LUTS) of benign prostatic enlargement to a statistically significantly greater extent than placebo, with no differences between the doses. However, treatment with tamsulosin OCAS 0.4 mg was associated with a lower ... Read More »
» Published in BJU Int. 2006 Nov;98 Suppl 2:13-7.
5. Ictal paralysis with tonic eye gazing mimicking a pontine infarction.
Match Strength: 2.979
PURPOSE: Concomitant positive and negative motor phenomena in a single seizure have not been reported before. METHOD: We used an extensive history review, neurological examination, EEG, MRI and SPECT study to demonstrate a rare combination of motor presentations as an ictal phenomenon. RESULT: A 64-year-old male was brought to the emergency room with dizziness, progressive drowsiness and left hemiparesis. A spontaneous eye deviation to the left side with nystagmus was observed. A right pontine lesion was tentatively diagnosed. However, a focal motor seizure of the patient's left face and limbs ... Read More »
» Published in Seizure. 2006 Dec;15(8):637-42. Epub 2006 Sep 22.
6. Epidemiology and treatment of pain in multiple sclerosis subjects.
Match Strength: 2.976
Symptom management in multiple sclerosis (MS) represents a primary focus for neurologists, data available in the literature on pain are lacking. There are no double-blind, parallel-arm, placebo-controlled trials and the majority of therapeutic approaches are taken from clinical experience. Pain syndromes can be classified as nociceptive somatic/visceral, neuropathic and psycogenic pain. Several studies has been recently pubblished addressing the prevalence of pain in MS subjects, finding a frequency of 40%. The principal neuropathic pain syndromes common in MS are trigeminal neuralgia (TN) and ... Read More »
» Published in Neurol Sci. 2006 Sep;27 Suppl 4:s291-3.
7. Phase I trial of PT-100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancy.
Match Strength: 2.654
PT-100 upregulates cytokine expression competitively inhibiting the dipeptidyl peptidase activity of fibroblast activation protein (FAP) and dipeptidyl peptidase IV (DPP-IV). This dose-escalation study was conducted to evaluate the safety of PT-100 in patients receiving myelosuppressive chemotherapy and to assess its effects on neutrophil recovery.PT-100 was administered orally for 7 days as a 200 microg, 400 microg, 800 microg, or 1,200 microg total daily dose (divided twice daily) to 6, 6, 17, and 5 patients, respectively. Patients received 2 cycles of chemotherapy: The first cycle served as ... Read More »
» Published in Cancer Invest. 2006 Oct;24(6):553-61.
|<< Prev 20 ||Showing results 1 to 7 of 7||Next 20 >>|
* All information on Level1Diet.com is for educational purposes only. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Before changing your diet, or adding supplements to your diet, or beginning an exercise program, everyone should consult a qualified and licensed health practitioner; a physician, dietician or similar professional.